[ÇÑÅõÁõ±Ç ÁøÈ«±¹] Á¦¾à/¹ÙÀÌ¿À µ¥Àϸ® ´º½º
¾È³çÇϼ¼¿ä ÇÑÅõÁõ±Ç Á¦¾à¹ÙÀÌ¿À ÁøÈ«±¹ÀÔ´Ï´Ù.
¢º️ÀüÀÏ ¹Ì±¹ ÁÖ¿ä À妽º
* ´Ù¿ì +0% S&P Á¦¾à -3.4% ³ª½º´Ú ¹ÙÀÌ¿À -4%
¢º️ÇØ¿Ü Peer ÀüÀÏ ÁÖ°¡
* ¼¿Æ®¸®¿Â °ü·Ã: Pfizer -2.5% J&J +0.4% Teva -3.2% Mylan -1.3%
* »ï¼º¹ÙÀÌ¿À °ü·Ã: Lonza -3% Merck -4.7% Roche -1% Amgen -3% Biogen -0.7%
* Çѹ̾àÇ° °ü·Ã: Sanofi -2.7% Spectrum -3.6%
* º¸Å彺: Allergan -3.7% Revance Therapeutic -5.2% Evolus -4.5%
* ±âŸ: Gilead Science -2% Regeneron -6.7% Abbvie -2.8% Celgene -0.3% Eli Lilly -2.9% CSL -1.9%
¢º️±¹³» À̽´
* ¹ÙÀÌ¿À½Ã¹Ð·¯ °ø¼¼¿¡ '¸®Åö»ê¡¤Çã¼Áƾ' À¯·´¸ÅÃâ ±Þ°¨
* ´ëÇüÁ¦¾à, ȸ»çä·Î ´ë±Ô¸ð ÀÚ±Ý Á¶´Þ...'½Å¿ëÀÇ Èû'
* º¹Çսžà Àü¼º½Ã´ë...·Î¼öÁ¬¡¤Åڹ̴©º¸¡¤µàÄ«ºê ±Þ¼ºÀå
* ÈĹßÁÖÀÚÀÇ ¿ª½À...¸¯½Ã¾Æ³ª, NOAC ºÐ±â¸ÅÃâ ù 1À§
* ¸Â¼ö »ç³ëÇÇ¡¤³ëº¸³ë, Àν¶¸°º¹ÇÕÁ¦ Á¾º´ ÁøÀÔ ¹ÚÂ÷
* CJÇコÄÉ¾î ±¹»ê½Å¾à 'ÄÉÀÌĸ', Á¾±Ù´ç°ú ¼Õ Àâ´Â´Ù
* ¸ÞµðÆ÷½ºÆ®, ÆóÁúȯġ·á Á¶¼º¹° ¹Ì±¹ ƯÇã Ãëµæ
* Çѽº¹ÙÀÌ¿À¸Þµå, ¹ÙÀÌ¿ÀÄÚ¸®¾Æ¼ 'ÈÞ½ºÅ²(HuSkin)' ¼±º¸ÀδÙ
* Â÷º´¿ø±×·ì "±Û·Î¹ú ÀÓ»ó¼¾ÅÍ, ÃʱâÀÓ»ó ä¬Çãºê µµ¾à"
¢º️ÇØ¿Ü À̽´
* Health Stocks Crumble as Fears of ¡®Medicare for All¡¯ Snowball
* ¾È¾à?¾È±¸ À±È°Á¦ ¸¶ÄÏ 2025³â 226¾ïÝ× ¡°ÁÖ¸£¸¤¡±
* ´ÙÀÌÀÌÂî»êÄì, µ¿ÅëÄ¡·áÁ¦ ¡®tarlige¡¯ ìí ¹ß¸Å
* J&J, 1/4ºÐ±â Á¦¾à ¸ÅÃâ 4.1% ¼ºÀå 102¾ïÝ×
* Jardiance: Diabetes drug sales ease Boehringer's patent-loss pain
* Roche's drugs, new and old, team up for major sales?sans price hikes
|
°¨»çÇÕ´Ï´Ù ¿À´ÃÀº ´Ù½Ã ´ã¾Æ¾ß °Ú½À´Ï´Ù¤¾
°¨»çÇÕ´Ï´Ù~